Thermo Fisher Scientific Inc.
TMO
$464.01
-0.13%
Thermo Fisher Scientific Inc. is a global leader in the healthcare sector, providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company operates as a dominant, integrated platform player across four key segments: analytical technologies, specialty diagnostics, life science solutions, and lab products and services, which includes contract research organization (CRO) capabilities. The current investor narrative centers on the company's post-pandemic normalization, as it transitions from the extraordinary COVID-19-related demand towards demonstrating resilient organic growth, operational efficiency, and strategic capital deployment, with recent news highlighting its ability to raise long-term guidance despite acknowledging new inflationary pressures and geopolitical tensions.…
TMO
Thermo Fisher Scientific Inc.
$464.01
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $603.21 and implied upside of +30.0% versus the current price.
Average Target
$603.21
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$371 - $603
Analyst target range
The stock is covered by 15 analysts, indicating strong institutional interest. The consensus sentiment is bullish, with recent institutional ratings showing a series of 'Buy' or 'Overweight' actions from major firms like Barclays, Citigroup, and Morgan Stanley, including an upgrade from Citigroup in December 2025. While a specific average target price and implied upside are not provided in the analyst data, the pattern of sustained bullish ratings and upgrades suggests analysts see value at current levels and believe in the company's long-term guidance.
The analyst target range, derived from revenue and EPS estimates, shows high conviction in the company's fundamental trajectory. The estimated revenue range for the forward period is tight, from $57.13 billion to $58.70 billion around an average of $58.18 billion. Similarly, the EPS estimate range is narrow, from $36.89 to $38.22. This tight clustering of estimates indicates strong analyst agreement on the company's near-term financial outlook, reducing uncertainty. The high target scenario likely assumes successful execution on margin initiatives and stable end-market demand, while the low target may factor in potential macroeconomic headwinds or incremental inflation pressures as flagged in recent company commentary.
Bulls vs Bears: TMO Investment Factors
The evidence currently tilts bearish in the near term, primarily due to the stock's severe technical breakdown and decelerating growth narrative, which have outweighed its strong fundamental underpinnings. However, the bearish case is largely priced in, with the stock trading 28% off its highs, while the bullish case rests on a high-quality business model that is now offering a more reasonable forward valuation. The single most important tension in the investment debate is the resolution of post-pandemic growth normalization: if TMO can demonstrate resilient organic growth above 5-7% while maintaining its industry-leading margins, the forward P/E of 17x will prove a compelling entry point; if growth stalls further, the premium trailing multiple remains at risk of compression.
Bullish
- Strong Profitability & Margin Expansion: The company's net margin improved from 14.54% in Q1 2025 to 16.17% in Q4 2025, demonstrating effective cost management. This is supported by a trailing twelve-month operating margin of 18.20% and robust free cash flow generation of $6.29 billion, providing significant financial flexibility.
- Attractive Forward Valuation: The forward P/E ratio of 17.05x is significantly lower than the trailing P/E of 32.34x, indicating the market expects a substantial earnings recovery. This forward multiple appears reasonable for a market leader with a diversified, recurring revenue base and could attract value investors.
- Resilient Recurring Revenue Streams: The company's largest revenue segments are consumables ($5.025B) and services ($4.97B), which provide stable, recurring income. This structural resilience supports steady demand, as evidenced by sequential quarterly revenue growth from $10.36B in Q1 to $12.22B in Q4 2025.
- Robust Financial Health: A strong balance sheet with a debt-to-equity ratio of 0.76 and a current ratio of 1.89 provides ample liquidity and low financial risk. The substantial free cash flow generation funds strategic capital deployment, including acquisitions and shareholder returns.
Bearish
- Severe Technical Downtrend: The stock is down 21.59% year-to-date and 18.18% over the past six months, significantly underperforming the S&P 500 by -27.9% over six months. Trading near the lower end of its 52-week range, it remains 28% below its high, reflecting persistent selling pressure and a lack of positive momentum.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 7.2% YoY, this represents a normalization from the pandemic-era surge. The multi-quarter growth rate is decelerating, and the company faces the challenge of demonstrating resilient organic growth in a post-COVID environment.
- Elevated Trailing Valuation: The trailing P/E of 32.34x trades at a premium to the sector, which may compress further if growth expectations are not met. The PEG ratio of 4.51 is high, suggesting the stock is expensive relative to its near-term earnings growth prospects.
- Macro & Inflationary Headwinds: Recent news highlights the company flagging 'modest inflation' risk amid Middle East tensions. These external pressures could squeeze margins and dampen end-market demand, particularly in capital-intensive segments like analytical instruments.
TMO Technical Analysis
The stock is in a pronounced downtrend, having declined 18.18% over the past six months and 21.59% year-to-date, significantly underperforming the broader market. As of the latest close of $464.61, the price is trading near the lower end of its 52-week range, approximately 28% above its 52-week low of $390.5 and 28% below its high of $643.99, positioning it in a zone that may attract value-oriented investors but also reflects persistent selling pressure. Recent momentum shows a modest short-term bounce, with a 3.75% gain over the past month, which contrasts sharply with the 2.06% loss over three months, suggesting a potential stabilization or oversold rebound attempt, though this is against a backdrop of severe longer-term weakness as evidenced by a -17.20 relative strength versus the S&P 500 over three months.
The divergence between the positive 1-month return and the negative 1-year return of 18.35% signals a potential inflection point, but it is too early to confirm a trend reversal given the stock's significant drawdown of -31.45% from its peak. The stock's beta of 0.87 indicates it has been slightly less volatile than the market during this turbulent period, which is atypical for a growth-oriented name and may suggest defensive positioning by investors. Key technical levels are clearly defined, with immediate resistance at the recent recovery high near $494 and major resistance at the 52-week high of $643.99; a sustained move above $500 is needed to signal a more credible recovery, while a breakdown below the $440-$450 support zone could open a path toward testing the 52-week low.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$393-$644
Price range past year
Annual Return
+16.6%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | -0.2% |
| 3m | -5.4% | +14.0% |
| 6m | -19.9% | +7.8% |
| 1y | +16.6% | +25.3% |
| ytd | -21.7% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth remains positive but has moderated from pandemic-era peaks, with Q4 2025 revenue of $12.215 billion representing a 7.2% year-over-year increase. The multi-quarter trend shows sequential revenue growth from Q1's $10.364 billion to Q4's $12.215 billion in 2025, indicating steady demand, though the growth rate is decelerating compared to the prior year's surge. Segment data, while not providing percentages, shows the consumables business ($5.025B) and service segment ($4.97B) as the largest revenue contributors, highlighting the company's resilient, recurring revenue streams which support stability.
The company is highly profitable, with Q4 2025 net income of $1.975 billion and a net margin of 16.17%. Gross margin for the quarter was a healthy 37.95%, and the trailing twelve-month operating margin stands at 18.20%, demonstrating strong pricing power and operational efficiency. Profitability metrics have shown stability, with the net margin improving from 14.54% in Q1 2025 to 16.17% in Q4, suggesting effective cost management even as revenue growth normalizes.
Financial health is robust, supported by a strong balance sheet and cash generation. The debt-to-equity ratio is a manageable 0.76, and the current ratio of 1.89 indicates ample liquidity. Most importantly, the company generated substantial free cash flow of $6.293 billion over the trailing twelve months, providing significant internal funding for dividends, share repurchases, and strategic acquisitions. Return on equity of 12.61% is solid, reflecting efficient use of shareholder capital.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 32.34x, while the forward PE is significantly lower at 17.05x, indicating the market expects a substantial recovery in earnings over the next twelve months. The wide gap between trailing and forward multiples reflects both the compression from the recent stock price decline and analyst expectations for earnings growth, as the forward EPS estimate of $37.78 implies a meaningful increase from recent quarterly levels.
Compared to sector averages, TMO's trailing PE of 32.34x trades at a premium, though specific industry average data is not provided in the valuation dataset for a quantified comparison. The premium is likely justified by the company's market-leading position, diversified revenue streams, and strong cash flow generation, which provide defensive characteristics and consistent growth potential that many peers lack. The forward PE of 17.05x appears more reasonable and could attract value investors if growth expectations are met.
Historically, the current trailing PE of 32.34x sits below the multi-year range observed in the historical ratios data, which has seen peaks above 40x during high-growth periods in 2021-2022. This suggests the stock is not at historical valuation extremes and may have room for multiple expansion if business performance stabilizes. However, it remains above the lows seen during market stress periods, indicating the market still ascribes a quality premium to the business model.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher's primary financial risk is not leverage or liquidity—its D/E of 0.76 and current ratio of 1.89 are strong—but rather margin pressure and growth sustainability. The company flagged 'modest inflation' as a new risk, which could threaten the recent margin expansion from 14.54% to 16.17% if pricing power wanes. Furthermore, revenue growth has decelerated to 7.2% YoY in Q4 2025, and the valuation (forward P/E 17.05x) is contingent on this growth rate being maintained or improved; a drop below 5% could trigger significant de-rating.
Market & Competitive Risks: The stock trades at a trailing P/E premium (32.34x) to the sector, creating valuation compression risk if growth stock multiples contract further in a higher-rate environment. Its beta of 0.87 indicates it has been less volatile than the market, but this defensive characteristic hasn't prevented a -31.45% drawdown, highlighting sector-specific rotation away from life science tools post-pandemic. Competitive risks are muted given its integrated platform dominance, but prolonged geopolitical tensions (as noted in recent news) could disrupt supply chains and capital spending in key end markets like biopharma.
Worst-Case Scenario: The worst-case scenario involves a stagflationary environment where persistent inflation erodes margins while a biotech funding winter and reduced government health spending cause organic revenue growth to turn negative. This could trigger a wave of analyst downgrades, compressing the forward P/E towards 14x. Combined with an earnings miss, the stock could re-test its 52-week low of $390.5, representing a downside of approximately -16% from the current price of ~$464. A breach of that level could see a fall to the $350-$370 range, implying a total potential loss of -20% to -25%.